drugset / Trial / NCT07271667
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of the study for Cohort 1 and Cohort 2 is to assess the anticancer activity of emavusertib in combination with zanubrutinib in participants with CLL.
Timeline
- Start
- 2026-04-23
- Primary completion
- 2027-11
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emavusertib | Small molecule | — | Oral |
| Background | Zanubrutinib | Small molecule | — | Oral |